Lack of Associations between XPC Gene Polymorphisms and Neuroblastoma Susceptibility in a Chinese Population

Table 2

Stratification analysis ofrisk genotypes and neuroblastoma susceptibility.

Variables

⁢rs2228001 (cases/controls)

Adjusted OR

P

⁢rs2228000 (cases/controls)

Adjusted OR

⁢rs2229090 (cases/controls)

Adjusted OR

AA

AC/CC

(95% CI)

CC

CT/TT

(95% CI)

GG

GC/CC

(95% CI)

Age, month

≤18

47/102

53/131

0.87 (0.54–1.39)

0.557

17/37

83/196

0.93 (0.49–1.74)

0.811

43/79

57/154

0.68 (0.42–1.10)

0.119

>18

52/116

101/182

1.24 (0.82–1.86)

0.304

17/39

136/259

1.20 (0.65–2.20)

0.559

56/112

97/186

1.04 (0.69–1.55)

0.862

Sex

Females

46/95

55/138

0.81 (0.50–1.30)

0.383

17/31

84/202

0.75 (0.39–1.43)

0.382

37/89

64/144

1.08 (0.66–1.74)

0.771

Males

53/123

99/175

1.31 (0.87–1.97)

0.190

17/45

135/253

1.40 (0.77–2.55)

0.270

62/102

90/196

0.75 (0.50–1.13)

0.167

Sites of origin

Adrenal gland

18/218

28/313

1.04 (0.56–1.94)

0.896

4/76

42/455

1.68 (0.58–4.85)

0.335

18/191

28/340

0.88 (0.47–1.64)

0.689

Retroperitoneal

37/218

48/313

0.90 (0.57–1.43)

0.654

14/76

71/455

0.84 (0.45–1.57)

0.582

36/191

49/340

0.75 (0.47–1.20)

0.226

Mediastinum

30/218

59/313

1.38 (0.86–2.22)

0.181

12/76

77/455

1.08 (0.56–2.08)

0.825

35/191

54/340

0.87 (0.55–1.38)

0.546

Other sites

11/218

14/313

0.92 (0.41–2.07)

0.837

3/76

33/455

1.31 (0.38–4.50)

0.670

8/191

17/340

1.16 (0.49–2.75)

0.734

Clinical stages

I + II + 4s

50/218

73/313

1.03 (0.69–1.54)

0.872

15/76

108/455

1.24 (0.68–2.24)

0.486

51/191

72/340

0.79 (0.53–1.18)

0.257

III + IV

46/218

75/313

1.09 (0.72–1.64)

0.680

17/76

104/455

0.95 (0.54–1.69)

0.863

47/191

74/340

0.90 (0.60–1.35)

0.599

Adjusted for age and gender.